Sutton Wealth Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Sutton Wealth Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-373	Closed	-$8.38K	–	1126
2018 Q1	$8.38K	Hold	373	–	–	0.01%	860
2017 Q4	$11.2K	Sell	373 -455	-55%	-$14.6K	0.01%	748
2017 Q3	$31.2K	Hold	828	–	–	0.02%	391
2017 Q2	$23.1K	Hold	828	–	–	0.02%	471
2017 Q1	$28.5K	Hold	828	–	–	0.02%	382
2016 Q4	$23.9K	Buy	+828	New	+$21.9K	0.02%	443
2016 Q3	–	Sell	-221	Closed	-$7.17K	–	1045
2016 Q2	$7.17K	Buy	+221	New	+$7.4K	0.01%	698

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Sutton Wealth Advisors's ACAD Position: Q2 2018 in Review

Sutton Wealth Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q2 2018, closing a stake of 373 shares — an estimated $8.38K sold.

Sutton Wealth Advisors first reported a position in ACAD in Q2 2016 and held it in 7 quarters. The position peaked at $31.2K in Q3 2017. 187 funds tracked by Wall St. Rank hold ACAD as of Q2 2018.

Sutton Wealth Advisors reported no remaining Acadia Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Sutton Wealth Advisors sold 373 Acadia Pharmaceuticals shares in Q2 2018, an estimated $8.38K.
Sutton Wealth Advisors first reported a position in Acadia Pharmaceuticals in Q2 2016 and held it in 7 quarters.
Sutton Wealth Advisors's Acadia Pharmaceuticals position peaked at $31.2K in Q3 2017.
187 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2018.

Based on Sutton Wealth Advisors's 13F filing for Q2 2018, filed 6 Nov 2023.